Form 4: Altimmune CBO's RSU Vesting and Tax Withholding

Altimmune's Chief Business Officer, Raymond M. Jordt, acquired 15,850 shares through RSU vesting and simultaneously disposed of 4,229 shares to cover tax obligations.

Summary

• Raymond M. Jordt, Chief Business Officer of Altimmune, Inc. (ALT), reported changes in his beneficial ownership.
• On January 27, 2026, Jordt acquired 15,850 shares of common stock through the vesting of Restricted Stock Units (RSUs).
• Concurrently, 4,229 shares were disposed of at a price of $6.18 per share to cover tax liabilities associated with the RSU vesting.
• Following these transactions, Jordt directly beneficially owns 65,536 shares of common stock and 47,550 Restricted Stock Units.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine compensation event for an executive, involving the vesting of Restricted Stock Units and a standard tax-related share disposition. It does not signal a significant change in company fundamentals or executive sentiment.

Positives

• Chief Business Officer Raymond M. Jordt received 15,850 shares of common stock through the vesting of Restricted Stock Units, indicating continued long-term incentive alignment with company performance.

Negatives

• 4,229 shares were disposed of to cover tax obligations, reducing the immediate direct shareholding.

Future Outlook

The remaining 47,550 Restricted Stock Units will continue to vest in substantially equal annual installments over the remaining period following January 27, 2025, subject to the reporting person's continued service through the applicable vesting date.

Industry Context

StockSavvy.ai notes that insider transaction reports like Form 4 are routine disclosures required by the SEC, providing transparency into executive stock ownership changes. These transactions, particularly RSU vestings and associated tax sales, are common and generally reflect pre-scheduled compensation events rather than discretionary trading based on new material information.

Stakeholder Impact

• Shareholders: Provides transparency into executive compensation and ownership structure.
• Employees: Reflects standard executive compensation practices, potentially impacting morale or perception of fairness.

Next Steps

• Remaining 47,550 Restricted Stock Units will vest in substantially equal annual installments over the remaining period following January 27, 2025, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details a routine RSU vesting and subsequent tax-related share disposition by a Chief Business Officer. Such transactions are typically pre-scheduled compensation events and do not reflect discretionary trading based on new material information about the company's performance or outlook. Therefore, it provides no new fundamental information to warrant a change in investment thesis, suggesting a 'hold' recommendation based solely on this filing.

Keywords

Altimmune, ALT, Form 4, insider transaction, RSU vesting, stock ownership, Chief Business Officer, Raymond Jordt